ClinicalTrials.gg
RecruitingNCT07417813Updated Feb 18, 2026

A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders

An observational study in Insomnia and Psychiatric Disorders, sponsored by Shanghai Mental Health Center. Recruiting at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Shanghai Mental Health Center · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
121
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Planned enrollment
27th of 36
121 · median 200
Started
2026
with 27 others
Observational
36 of 198
18 open now
Primary completion
2026-08
later than 44 of 87 live
Registered
171st of 198
by date
Lead sponsor
6 of 198
Shanghai Mental Health Center

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 27th largest by planned enrollment of the 36 observational ones that give a count, is one of 28 that started in 2026, is one of 36 observational ones, reaches primary completion later than 44 of the 87 other live ones, and was the 171st registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness and safety of lemborexant (a new dual orexin receptor antagonist) in the treatment of patients with mental disorders complicated with insomnia. The subjects are patients aged 18 years and above, who meet the DSM-5 diagnostic criteria for mental disorders and have an Insomnia Severity Index (ISI) score ≥11. They will receive lemborexant treatment for 8 weeks, with follow-up to observe the improvement of insomnia symptoms and adverse events, so as to provide real-world evidence for the clinical optimization of treatment regimens for insomnia comorbid with psychiatric disorders.

Read the detailed description

Background: The incidence of insomnia in patients with psychiatric disorder is as high as 70%-80%. Traditional benzodiazepine receptor agonists have risks such as addiction and cognitive impairment. Lemborexant was approved for marketing in China in 2025, but its real-world data in the population with insomnia comorbid with psychiatric disorder is insufficient. Hypothesis: 8-week treatment with lemborexant can significantly improve insomnia symptoms in insomnia comorbid with psychiatric disorders, with good safety. Design: A multicenter, prospective, single-arm, observational study. It is planned to enroll 121 patients (with an expected dropout rate of 30%), who will receive 8-week treatment. Efficacy will be evaluated by scales such as ISI and VAS, and adverse events will be monitored.

03

Conditions studied

  • Insomnia
  • Psychiatric Disorders

Keywords

  • Lemborexant
  • Psychiatric Disorders
  • Insomnia
  • Dual Orexin Receptor Antagonist
  • Real-World Study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults ≥18 years with any DSM-5-diagnosed mental disorder, ISI score ≥11, ≥7 hours available sleep time, ability to complete 2-month assessments/follow-up, voluntary informed consent, and clinical indication for lemborexant treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years and above, regardless of gender;
  2. Meet the diagnostic criteria for mental disorders (any type);
  3. Insomnia Severity Index (ISI) score ≥11;
  4. Have at least 7 hours of sleep time available;
  5. Able to complete the 2-month scale assessment and follow-up plan;
  6. Voluntarily sign the form;
  7. Intend to receive lemborexant treatment as judged by the clinicians

Exclusion criteria

Exclusion Criteria:

  1. Mental disorder is in the acute phase as judged by clinical assessment, or the dose of other psychotropic drugs cannot be stabilized during the study;
  2. Concurrent use of ≥2 types of benzodiazepine receptor agonists (BZRAs) as insomnia treatment drugs;
  3. Previous continuous use of dual orexin receptor antagonist (DORA)-type drugs for >1 week;
  4. Clear suicide attempt/plan or high suicide risk as judged by the researcher;
  5. Pregnant or lactating women;
  6. Patients with narcolepsy;
  7. Patients with severe hepatic insufficiency;
  8. Currently accompanied by severe or unstable diseases of cardiovascular, respiratory, digestive and other systems;
  9. Other conditions deemed unsuitable for participation by the researcher
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
121 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lemborexant Treatment Group

    All enrolled patients receive lemborexant treatment, with a study cycle of 8 weeks (including a baseline assessment period ≤1 week and an 8-week treatment observation period)

    Drug: Lemborexant tablets

Interventions

  • DrugLemborexantStudies of LemborexantLemborexant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lemborexant Tablets (Dayvigo® tablets 5 mg): Oral administration, taken before bedtime. The initial dose is 5mg/day, which can be adjusted to 10mg/day (maximum dose: 10mg/day) based on clinical response and tolerability. For patients using benzodiazepine receptor agonists(BZRAs) at baseline, it is recommended to gradually reduce and discontinue BZRAs within the first 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Insomnia Severity Index (ISI) Score from Baseline

    Change in Insomnia Severity Index (ISI) Score from Baseline: Evaluated by the ISI scale (7 items, total score 0-28 points).

    Time frame: Measurement time points: Baseline, Week 4 of treatment, Week 8 of treatment

Secondary outcomes

  1. ISI Treatment Response Rate

    Proportion of patients with an ISI score decrease of ≥7 points from baseline.

    Time frame: Measurement time points: Week 4 and Week 8 of treatment

  2. ISI Remission Rate

    Proportion of patients with an ISI score \<8 points.

    Time frame: Measurement time points: Week 4 and Week 8 of treatment

  3. Change in Sleep Satisfaction VAS Score

    Including 3 dimensions (sleep onset efficiency, sleep maintenance, impact on daytime function) with 1-10 points for each dimension.

    Time frame: Measurement time points: Baseline, Week 4 and Week 8 of treatment

  4. Change in Epworth Sleepiness Scale (ESS) Score

    Change in Epworth Sleepiness Scale (ESS) Score: Total score 0-24 points.

    Time frame: Measurement time points: Baseline, Week 4 and Week 8 of treatment

  5. Lemborexant Treatment Retention Rate

    Lemborexant Treatment Retention Rate: Proportion of patients still using lemborexant at Week 4 and Week 8 of treatment;

    Time frame: Week 4 and Week 8 of treatment

  6. BZRAs Discontinuation Rate

    Discontinuation rate of patients using BZRAs at baseline

    Time frame: Measurement time points: Week 4 and Week 8 of treatment

  7. BZRAs Dose Change

    Change in diazepam-equivalent dose from baseline

    Time frame: Measurement time points: Week 4 and Week 8 of treatment

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.

Of 127 non-industry observational studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's planned 7 months is below that.

Counting every sponsor, half of 138 studies reached it within 18 months; a quarter within 4 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 18, 2026
StartActual
Jan 24, 2026
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07417813
Collaborators
RenJi Hospital, Shanghai Fengxian District Mental Health Center, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Ningbo University, Xuzhou Oriental People's Hospital, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Suzhou Guangji Hospital
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Jan 24, 2026
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Wenzheng Wang, PhD
Contact
fffty@163.com
18017311500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion